BMAC & Allograft vs BMP-2



Status:Recruiting
Conditions:Orthopedic
Therapuetic Areas:Orthopedics / Podiatry
Healthy:No
Age Range:18 - Any
Updated:1/30/2019
Start Date:July 24, 2018
End Date:July 2019
Contact:Peter Passias
Email:peter.passias@nyumc.org
Phone:212-231-5470

Use our guide to learn which trials are right for you!

Prospective, Blinded, Non-randomized Study of Thoracolumbar Spinal Fusion Graft Efficacy: Bone Marrow Aspirate Concentrate and Allograft Versus Recombinant Bone Morphogenetic Protein-2 (BMP)

The aim of this investigation is to compare the use of bone marrow aspirate concentrate
(BMAC) and allograft versus to recombinant human bone morphogenetic protein-2 (BMP) in
subjects undergoing elective thoracolumbar spinal fusion with interbody support. The
investigators will look at the safety and efficacy of these two different surgical methods by
assessing surgery outcomes and participants' quality of life.

Currently, there are many available orthopaedic graft adjuncts which each have their own
advantages and disadvantages. For example, although effective, BMPs are very expensive and
have a risk of side effects. The use of BMAC may be a good alternative to the use of BMPs,
and may not have the same side effects.

Subjects who are scheduled for an elective spinal fusion and are enrolled in the study will
be assigned to receive either BMP or BMAC. Subjects will be asked to complete questionnaires
relating to quality of life, use of pain killers, and overall health, as well as have
standard radiographic studies to examine the spine pre- and post-surgically. Subjects will
attend 7 visits, which happen at the same time as the standard of care visits they would
normally attend for their condition. Subjects will be followed in the study for 2 years in
total.

Inclusion Criteria:

- Must be 18 years old or older

- Scheduled for elective posterior or anterior and posterior spinal fusion of the
thoracolumbar spine with or without anterior interbody support

- Failed at least 6 weeks of conservative care

- No contraindication to BMAC (as per manufacturer)

- Signed consent form

Exclusion criteria:

- Prior lumbar fusion surgery at operative level (prior discectomy and/or laminectomy
allowed)

- Incompetent or missing anterior arch at the affected level (e.g. laminectomy, pars
defect)

- Currently requires laminectomy at level of surgery

- Facet joints at implant level are absent or fractured

- Post-traumatic vertebral body compromise or acute fracture at implant level

- Body mass Index (BMI) > 40

- Known allergy to titanium

- Paget's disease, osteomalacia, or any other metabolic bone disease

- Use of medications or any drug known to potentially interfere with bone/soft tissue
healing (e.g. chronic systemic steroids)

- Unlikely to comply with the follow-up evaluation schedule

- Active malignancy defined as history of invasive malignancy, except if the subject has
received treatment and displayed no clinical signs and symptoms for at least five
years

- Pregnant or planning to become pregnant during the length of study participation
We found this trial at
1
site
550 1st Ave
New York, New York 10016
(212) 263-7300
Principal Investigator: Peter Passias, MD
Phone: 212-231-5470
New York University School of Medicine NYU School of Medicine has a proud history that...
?
mi
from
New York, NY
Click here to add this to my saved trials